CAS No.: | 1401708-83-5 |
---|---|
Formula: | C27h44n4o5 |
EINECS: | 227-005-2 |
Type: | Pharmaceutical Intermediates |
Appearance: | Powder |
Quality: | Technical |
Samples: |
---|
Suppliers with verified business licenses
Product name | Dihexa |
MOQ | 5mg/10mg |
CAS NO |
1401708-83-5 |
Purity | NLT 98% |
Appearance | White powder |
Density | 504.66 |
Product description
What is DIHEXA Peptide?
Dihexa (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is anoligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte-growth-factor () and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor.
According to a patent, "Short duration safety studies with Dihexa have uncovered no apparent toxicity. Of particular note is a lack of neoplastic induction, since c-Met is recognized as an oncogene. This is unsurprising sinceoncogenesis requires multiple mutations including both oncogene induction and tumor suppressor attenuation."
DIHEXA Peptide Benefits
Dihexa dramatically improves cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor.
These statements have not been evaluated by the fda and are not intented to diagnose, treat, cure or prevent any disease.
Suppliers with verified business licenses